Mental healthcare company focusing of accelerating patient access to evidence-based in mental health COMPASS Pathways Plc. (NASDAQ: CMPS) announced having received its fifth patent from the United States Patent and Trademark Office (USPTO). This patent covers crystalline psilocybin.
This goes down as the 10th overall patent COMPASS Pathways has received. Five of them have been issued in the United States, two in the UK, two in Hong Kong, and one in Germany.
The newly issued patent covers methods used in treatment of treatment-resistant depression (TRD) using crystalline psilocybin and also with oral dosage of crystalline psilocybin. The new patent takes the registration US Patent No 11,180,517.
The crystalline psilocybin was used in COMP360, the company synthesized psilocybin formulation which is being developed for psilocybin treatment in TRD. The company’s co-founder and chief executive officer, George Goldsmith, says this new patent has reinforced the company’s strong patent base.
“This 10th patent is a strong testament to our innovation. Patents enable us to continue to do the highest quality clinical research so we can work to bring therapies to patients who are suffering with serious mental health challenges and have few options,” said the CEO.
